Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Psychiatric Manifestation in Patients with Parkinson's Disease

  • Han, Ji Won (Department of Neuropsychiatry, Seoul National University Bundang Hospital) ;
  • Ahn, Yebin D. (Department of Neuropsychiatry, Seoul National University Bundang Hospital) ;
  • Kim, Won-Seok (Department of Rehabilitation Medicine, Seoul National University Bundang Hospital) ;
  • Shin, Cheol Min (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Jeong, Seong Jin (Department of Urology, Seoul National University Bundang Hospital) ;
  • Song, Yoo Sung (Department of Nuclear Medicine, Seoul National University Bundang Hospital) ;
  • Bae, Yun Jung (Department of Radiology, Seoul National University Bundang Hospital) ;
  • Kim, Jong-Min (Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital)
  • Received : 2018.08.31
  • Accepted : 2018.10.11
  • Published : 2018.11.19
⟨ Previous Next ⟩

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder. Although its major manifestation is motor symptoms, resulting from the loss of dopaminergic neurons in the substantia nigra, psychiatric symptoms, such as depression, anxiety, hallucination, delusion, apathy and anhedonia, impulsive and compulsive behaviors, and cognitive dysfunction, may also manifest in most patients with PD. Given that the quality of life - and the need for institutionalization - is so highly dependent on the psychiatric well-being of patients with PD, psychiatric symptoms are of high clinical significance. We reviewed the prevalence, risk factors, pathophysiology, and treatment of psychiatric symptoms to get a better understanding of PD for improved management.

Keywords

References

  1. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14(2):317-35. https://doi.org/10.1016/S0733-8619(05)70259-0
  2. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67(4):492-6. https://doi.org/10.1136/jnnp.67.4.492
  3. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-45. https://doi.org/10.1016/S1474-4422(06)70373-8
  4. Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18(7):435-50. https://doi.org/10.1038/nrn.2017.62
  5. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23(2):183-9. https://doi.org/10.1002/mds.21803
  6. Aarsland D, Kramberger MG. Neuropsychiatric symptoms in Parkinson's disease. J Parkinsons Dis 2015;5(3):659-67. https://doi.org/10.3233/JPD-150604
  7. Starkstein SE, Brockman S. Management of depression in Parkinson's disease a systemic review. Mov Disord 2017;4(4):470-7.
  8. Torbey E, Pachana NA, Dissanayaka NN. Depression rating scales in Parkinson's disease: a critical review updating recent literature. J Affect Disord 2015;184:216-24. https://doi.org/10.1016/j.jad.2015.05.059
  9. Marsh L, McDonald WM, Cummings J, Ravina B; NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21(2):148-58. https://doi.org/10.1002/mds.20723
  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
  11. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23(2):183-9. https://doi.org/10.1002/mds.21803
  12. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002;17(3):445-54. https://doi.org/10.1002/mds.10114
  13. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128(Pt 6):1314-22. https://doi.org/10.1093/brain/awh445
  14. Zhuo C, Xue R, Luo L, Ji F, Tian H, Qu H, et al. Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine (Baltimore) 2017;96(22):e6698. https://doi.org/10.1097/MD.0000000000006698
  15. Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM. Efficacy and tolerability of antidepressants in Parkinson's disease: a systematic review and network meta-analysis. Int J Geriatr Psychiatry 2018;33(4):642-51. https://doi.org/10.1002/gps.4834
  16. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886-92. https://doi.org/10.1212/01.wnl.0000336340.89821.b3
  17. Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS One 2013;8(11):e79510. https://doi.org/10.1371/journal.pone.0079510
  18. Xie CL, Wang XD, Chen J, Lin HZ, Chen YH, Pan JL, et al. A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson's disease patients. Neurol Sci 2015;36(6):833-43. https://doi.org/10.1007/s10072-015-2118-0
  19. Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2015;21(8):833-42. https://doi.org/10.1016/j.parkreldis.2015.04.018
  20. Lee T, Lee HB, Ahn MH, Kim J, Kim MS, Chung SJ, et al. Increased suicide risk and clinical correlates of suicide among patients with Parkinson's disease. Parkinsonism Relat Disord 2016;32:102-7. https://doi.org/10.1016/j.parkreldis.2016.09.006
  21. RN WL, Masoon MA, Acharyya S, NG HL, Tay KY, Au WL, et al. Suicide in Parkinson's disease. Mov Disord Clin Pract 2018;5(2):177-82. https://doi.org/10.1002/mdc3.12599
  22. Kostic VS, Pekmezovic T, Tomic A, Jecmenica-Lukic M, Stojkovic T, Spica V, et al. Suicide and suicidal ideation in Parkinson's disease. J Neurol Sci 2010;289(1-2):40-3. https://doi.org/10.1016/j.jns.2009.08.016
  23. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131(Pt 10):2720-8. https://doi.org/10.1093/brain/awn214
  24. Chen JJ, Marsh L. Anxiety in Parkinson's disease: identification and management. Ther Adv Neurol Disorder 2014;7(1):52-9. https://doi.org/10.1177/1756285613495723
  25. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8(3):193-7. https://doi.org/10.1016/S1353-8020(01)00015-3
  26. Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014;29(8):1035-43. https://doi.org/10.1002/mds.25919
  27. Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol 2017;13(2):81-95. https://doi.org/10.1038/nrneurol.2016.200
  28. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007;22(8):1061-8. https://doi.org/10.1002/mds.21382
  29. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67(4):416-21. https://doi.org/10.1001/archneurol.2010.35
  30. Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson's disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis 2016;50(3):733-40. https://doi.org/10.3233/JAD-150818
  31. Jethwa KD, Onalaja OA. Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis. BJPsych Open 2015;1(1):27-33. https://doi.org/10.1192/bjpo.bp.115.000927
  32. Martinez-Ramirez D, Okun MS, Jaffee MS. Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. Neurodegener Dis Manag 2016;6(4):319-30. https://doi.org/10.2217/nmt-2016-0009
  33. Schneider RB, Iourinets J, Richard IH. Parkinson's disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag 2017;7(6):365-76. https://doi.org/10.2217/nmt-2017-0028
  34. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 2007;17(3):165-71. https://doi.org/10.1016/j.euroneuro.2006.08.007
  35. National Institute for Health and Care Excellence. Parkinson's Disease: Diagnosis and Management in Primary and Secondary Care (Clinical Guideline CG35). London: National Institute for Health and Care Excellence; 2006.
  36. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991;3(3):243-54. https://doi.org/10.1176/jnp.3.3.243
  37. Lanctot KL, Aguera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement 2017;13(1):84-100. https://doi.org/10.1016/j.jalz.2016.05.008
  38. Kaji Y, Hirata K. Apathy and anhedonia in Parkinson's disease. ISRN Neurol 2011;2011:219427.
  39. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015;14(5):518-31. https://doi.org/10.1016/S1474-4422(15)00019-8
  40. Drijgers RL, Dujardin K, Reijnders JS, Defebvre L, Leentjens AF. Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 2010;16(10):656-60. https://doi.org/10.1016/j.parkreldis.2010.08.015
  41. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77(5):579-84. https://doi.org/10.1136/jnnp.2005.075929
  42. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14. https://doi.org/10.1212/WNL.44.12.2308
  43. Dujardin K, Langlois C, Plomhause L, Carette AS, Delliaux M, Duhamel A, et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord 2014;29(14):1796-801. https://doi.org/10.1002/mds.26058
  44. Devos D, Moreau C, Maltete D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014;85(6):668-74. https://doi.org/10.1136/jnnp-2013-306439
  45. Thobois S, Lhommee E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013;136(Pt 5):1568-77. https://doi.org/10.1093/brain/awt067
  46. Camargos EF, Quintas JL. Apathy syndrome treated successfully with modafinil. BMJ Case Rep 2011;2011:pii: bcr0820114652.
  47. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26 Suppl 3:S42-80. https://doi.org/10.1002/mds.23884
  48. Lou JS. Fatigue in Parkinson's disease and potential interventions. NeuroRehabilitation 2015;37(1):25-34. https://doi.org/10.3233/NRE-151238
  49. Pena E, Mata M, Lopez-Manzanares L, Kurtis M, Eimil M, Martinez-Castrillo JC, et al. Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid. Neurologia 2016;33(6):395-402.
  50. Grandas F, Lopez-Manzanares L. Bupropion-induced parkinsonism. Mov Disord 2007;22(12):1830-1. https://doi.org/10.1002/mds.21425
  51. Cheng WC, Liu CM, Hsieh MH, Hwang TJ. Bupropion-related parkinsonism and dystonia. J Clin Psychopharmacol 2009;29(6):616-8. https://doi.org/10.1097/JCP.0b013e3181c07a3f
  52. Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91(3):e189-201. https://doi.org/10.1212/WNL.0000000000005816
  53. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63(7):969-73. https://doi.org/10.1001/archneur.63.7.969
  54. Leeman RF, Billingsley BE, Potenza MN. Impulse control disorders in Parkinson's disease: background and update on prevention and management. Neurodegener Dis Manag 2012;2(4):389-400. https://doi.org/10.2217/nmt.12.35
  55. Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, et al. International validation of a behavioral scale in Parkinson's disease without dementia. Mov Disord 2015;30(5):705-13. https://doi.org/10.1002/mds.26223
  56. Lee JY, Seo SH, Kim YK, Yoo HB, Kim YE, Song IC, et al. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry 2014;85(1):23-30. https://doi.org/10.1136/jnnp-2013-305549
  57. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132(Pt 5):1376-85. https://doi.org/10.1093/brain/awp054
  58. Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, et al. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord 2010;25(11):1660-9. https://doi.org/10.1002/mds.23147
  59. Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol 2011;69(6):986-96. https://doi.org/10.1002/ana.22356
  60. van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010;75(19):1711-6. https://doi.org/10.1212/WNL.0b013e3181fc27fa
  61. Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: Neurobiological basis. Mov Disord 2016;31(8):1103-13. https://doi.org/10.1002/mds.26587
  62. Halbig TD, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009;16(4):493-7. https://doi.org/10.1111/j.1468-1331.2008.02509.x
  63. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, Alegre M, Toledo J, Valencia M, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2011;134(Pt 1):36-49. https://doi.org/10.1093/brain/awq301
  64. Okun MS, Weintraub D. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord 2013;28(14):1915-9. https://doi.org/10.1002/mds.25735
  65. Kim A, Kim YE, Kim HJ, Yun JY, Yang HJ, Lee WW, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. Parkinsonism Relat Disord 2018:pii: S1353-8020(18)30313-4.
  66. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78(1):36-42. https://doi.org/10.1136/jnnp.2005.083113
  67. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22(12):1689-707. https://doi.org/10.1002/mds.21507
  68. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349-56. https://doi.org/10.1002/mds.24893
  69. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017;89(1):88-100. https://doi.org/10.1212/WNL.0000000000004058
  70. Wood LD, Neumiller JJ, Setter SM, Dobbins EK. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother 2010;8(4):294-315. https://doi.org/10.1016/j.amjopharm.2010.08.002
  71. Halliday G, Lees A, Stern M. Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord 2011;26(6):1015-21. https://doi.org/10.1002/mds.23669
  72. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry 1980;137(5):535-44. https://doi.org/10.1176/ajp.137.5.535
  73. Nazem S, Siderowf AD, Duda JE, Brown GK, Ten Have T, Stern MB, et al. Suicidal and death ideation in Parkinson's disease. Mov Disord 2008;23(11):1573-9. https://doi.org/10.1002/mds.22130
  74. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73(21):1738-45. https://doi.org/10.1212/WNL.0b013e3181c34b47

Cited by

  1. Odorants: a tool to provide nonpharmacological intervention to reduce anxiety during normal and pathological aging vol.82, pp.None, 2019, https://doi.org/10.1016/j.neurobiolaging.2019.06.007
  2. Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review vol.7, pp.3, 2018, https://doi.org/10.1002/mdc3.12899
  3. Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists vol.35, pp.28, 2018, https://doi.org/10.3346/jkms.2020.35.e230
  4. The Role of Alpha-Synuclein and Other Parkinson’s Genes in Neurodevelopmental and Neurodegenerative Disorders vol.21, pp.16, 2018, https://doi.org/10.3390/ijms21165724
  5. Differences in correlations of depression and anhedonia with cardiovascular sympathetic functions during a head-up tilt test in drug-naïve Parkinson’s disease patients vol.41, pp.10, 2018, https://doi.org/10.1007/s10072-020-04390-w
  6. Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection vol.10, pp.1, 2020, https://doi.org/10.1038/s41598-020-77652-4
  7. FUNCTIONAL NEUROMARKERS IN PARKINSON’S DISEASE (PD) vol.19, pp.2, 2018, https://doi.org/10.5604/01.3001.0014.8146
  8. Apathy and Anhedonia: Clinical and Neurophysiological Assessment of a Romanian Cohort vol.11, pp.6, 2018, https://doi.org/10.3390/brainsci11060729
  9. Mood Disorders and Anxiety in Parkinson’s Disease: Current Concepts vol.34, pp.4, 2018, https://doi.org/10.1177/08919887211018267
  10. Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases vol.22, pp.16, 2018, https://doi.org/10.3390/ijms22169082
  11. Parkinson’s Disease and Deep Brain Stimulation Have an Impact on My Life: A Multimodal Study on the Experiences of Patients and Family Caregivers vol.18, pp.18, 2021, https://doi.org/10.3390/ijerph18189516
  12. Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson’s disease vol.25, pp.10, 2018, https://doi.org/10.1080/14728222.2021.1999928